Facial angle and downs syndrome in fetus vs NIPT
Reading File
Finding Sources
Finding Sources
Searching PubMed
"facial angle" ultrasound "Down syndrome" prenatal
Searching PubMed
NIPT "cell-free DNA" "Down syndrome" screening accuracy
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
NIPT "cell-free DNA" trisomy 21 sensitivity specificity
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Searching the Web
frontomaxillary facial angle Down syndrome trisomy 21 first trimester screening 2023 2024
I now have comprehensive information from the textbooks and web sources. Let me compile the full answer.
Facial Angle (Frontomaxillary Facial Angle) vs. NIPT for Down Syndrome (Trisomy 21) Detection
1. The Frontomaxillary Facial (FMF) Angle
What It Is
The frontomaxillary facial (FMF) angle is an ultrasound measurement taken on the midsagittal plane of the fetal face, typically at 11+0 to 13+6 weeks. It measures the angle between the upper surface of the maxilla and a line projected from the frontomaxillary suture to the most anterior point of the maxilla. Flat facies ("mid-face hypoplasia") is one of the most recognizable phenotypic features of Down syndrome, and this measurement quantifies it objectively. The flatter the mid-face, the larger the FMF angle. The underlying cause is thought to be abnormal connective tissue in trisomy 21 fetuses.
How It's Measured
- Performed in the midsagittal plane (same plane used for nuchal translucency)
- FMF angle >85th percentile for gestational age is considered abnormal
- In trisomy 21 fetuses, the angle is typically >88 degrees (mean ~83-85 degrees in euploid fetuses at 11-14 weeks)
- Can be performed with 2D or 3D ultrasound; 3D allows more precise plane definition
Performance as a Screening Marker
| Parameter | Value |
|---|---|
| FMF angle alone, detection rate for T21 | ~55-65% (sensitivity) |
| False-positive rate (euploid fetuses) | ~5% |
| Likelihood ratio (positive) | ~5-6x |
| Combined with NT + nasal bone + NT | Detection rate rises to ~90-95% |
- The FMF angle is used as an adjunct marker, not a standalone screen
- As an isolated marker, the likelihood ratio for trisomy 21 is approximately 5-6 fold when abnormal
- It is most powerful when combined with nuchal translucency (NT), maternal serum PAPP-A, and free beta-hCG in first-trimester combined screening
- Creasy & Resnik notes the FMF angle is among the "inconsistently used" second-trimester markers because of time and expertise requirements, alongside prenasal thickness and iliac wing angle. (Creasy & Resnik's Maternal-Fetal Medicine, block 6)
Other First-Trimester Ultrasound Markers for Down Syndrome (context)
| Marker | Sensitivity for T21 | FPR |
|---|---|---|
| Nuchal translucency (NT) alone | ~73% | 5% |
| Absent/hypoplastic nasal bone | ~73% (first trimester) | 0.5% |
| Frontomaxillary facial angle | ~55-65% | 5% |
| Tricuspid regurgitation | ~55% | 1% |
| Ductus venosus PI | ~66% | 3% |
- NT is the single most powerful first-trimester ultrasound marker
- The FMF angle contributes incremental detection when layered on top of NT and nasal bone
2. NIPT (Non-Invasive Prenatal Testing / Cell-Free DNA)
Mechanism
NIPT analyzes cell-free DNA (cfDNA) fragments in maternal blood from 10 weeks gestation onwards. These fragments are primarily placental trophoblast-derived DNA mixed with maternal cfDNA. Various methods (shotgun sequencing, targeted sequencing, SNP-based approaches) quantify the proportion of fetal chromosomal material to detect aneuploidy. The "fetal fraction" (proportion of cfDNA that is placental-derived) needs to be adequate (typically >4%) for a result.
As stated in Henry's Clinical Diagnosis: "As a screening test for detection of trisomies 18, 21, and 13, accuracy is being reported as approximately 98% to 99%."
NIPT Performance for Trisomy 21
| Metric | Value |
|---|---|
| Sensitivity for T21 | >99% |
| Specificity | >99.8% |
| Positive predictive value (PPV) | ~80-90% (high-risk population), lower in general population |
| False-positive rate | ~0.1-0.3% |
| Negative predictive value | ~99.9% |
- PPV is population-dependent: in a 35-year-old woman, PPV for T21 is ~80%. In a 25-year-old (lower prior risk), PPV may be ~40-50% despite the same sensitivity/specificity.
- NIPT is a screening test, NOT a diagnostic test. Positive results must be confirmed by karyotype (via amniocentesis or CVS).
NIPT Limitations
- Confined placental mosaicism: cfDNA reflects placental DNA, not necessarily fetal DNA. This is the major cause of false-positive or false-negative results.
- Low fetal fraction: occurs with maternal obesity, early gestation, multiple gestation - can give a "no-call" result
- Vanishing twin: can cause discordant results
- Maternal malignancy: can introduce tumor-derived cfDNA
- No-call rate: ~1-5% of samples are non-reportable
- Sex chromosome aneuploidies: higher false-positive rates (especially for Turner syndrome / 45,X)
- Genome-wide microdeletion screening by NIPT is currently not recommended for the general obstetric population (ACOG)
3. Head-to-Head Comparison
| Feature | FMF Angle | NIPT (cfDNA) |
|---|---|---|
| Timing | 11-14 weeks (1st trimester) | From 10 weeks |
| Nature | Ultrasound measurement | Blood test (cfDNA) |
| Sensitivity for T21 | ~55-65% | >99% |
| Specificity | ~95% | >99.8% |
| Role | Adjunct marker; boosts combined screen | Primary high-sensitivity screen |
| Invasiveness | Non-invasive (US) | Non-invasive (venipuncture) |
| Cost | Low (part of routine anatomy scan) | Moderate-high |
| Expertise required | Yes (sonographer training, strict plane) | No (lab-based) |
| Confirms diagnosis? | No | No (still requires amniocentesis) |
| Detects other anomalies | Yes (structural) | Limited to specific chromosomes/CNVs |
| Best use | Part of first-trimester combined screen | High-sensitivity screen, especially post intermediate-risk combined test |
4. Clinical Workflow Context
Current practice (per major guidelines) is a tiered approach:
- First-trimester combined screening (10-13+6 weeks): NT + maternal serum PAPP-A + free beta-hCG ± nasal bone. Detection rate ~85-93% for T21 at 5% FPR.
- FMF angle may be added as an adjunct marker to adjust the combined screening risk (using likelihood ratios). Particularly useful in the intermediate-risk range.
- NIPT: offered to all (universal) or after intermediate/high-risk combined screen. Dramatically superior sensitivity for T21 compared to any ultrasound marker.
- Definitive diagnosis: Only by karyotype from amniocentesis or CVS.
The FMF angle is best understood as a refinement tool within the first-trimester ultrasound screen, whereas NIPT represents a fundamentally different, much higher-sensitivity platform. The FMF angle cannot replace NIPT for trisomy 21 screening but retains value in settings where NIPT is unavailable or unaffordable, and as part of the structural fetal assessment.
Key sources:
- Creasy & Resnik's Maternal-Fetal Medicine - Chapters 30 & 18 (ultrasound markers, FMF angle, NIPT)
- Henry's Clinical Diagnosis and Management by Laboratory Methods - Chapter 71 (prenatal NIPT/cfDNA)
- Fetal Medicine USA - First Trimester Screening overview
- Prenatal Screening for Chromosomal Defects - Fetal Medicine Barcelona 2024
This is a shared conversation. Sign in to Orris to start your own chat.